{"id":"W4410950112","doi":"10.1080/14796694.2025.2502318","title":"rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Cabazitaxel; Prostate cancer; Androgen receptor; Abiraterone acetate; Oncology; Internal medicine; Docetaxel; Randomized controlled trial; Clinical endpoint; Clinical trial; Androgen deprivation therapy; Pharmacology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005640734,0.0002096448,0.001095281,0.0002248045,0.000082823,0.000007661271,0.0001765547,0.0003069627,0.00009666892],"category_scores_gemma":[0.0008655952,0.0001095019,0.0001569962,0.0008784712,0.0003633943,0.00004631119,0.00006458842,0.0004824834,0.000003886184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003520672,"about_ca_system_score_gemma":0.001756993,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001318959,"about_ca_topic_score_gemma":0.0001706966,"domain_scores_codex":[0.9979261,0.0006061128,0.0004969042,0.0003301346,0.000306116,0.0003346483],"domain_scores_gemma":[0.9985965,0.0004514974,0.0002188372,0.000348387,0.0002252995,0.0001594543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9512183,0.00208727,0.01767631,0.00009878707,0.0004713754,0.00001060903,0.0005517105,2.390344e-7,0.0006178711,0.0001128929,0.02119293,0.00596172],"study_design_scores_gemma":[0.9238865,0.002518702,0.002449076,0.0002407867,0.0002973759,0.000001344307,0.00007390027,0.00001448161,0.007003207,0.0000704066,0.06334203,0.0001022301],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9790488,0.001203881,0.000002665599,0.01166757,0.001257431,0.004864821,0.00003471898,0.0000509133,0.001869238],"genre_scores_gemma":[0.9849986,0.0008883504,0.0009088865,0.002634306,0.001079547,0.00151275,0.0004242924,0.00005978864,0.00749351],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0421491,"threshold_uncertainty_score":0.4465359,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01713607726596698,"score_gpt":0.3317622043259618,"score_spread":0.3146261270599948,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}